Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antibody Structure01:10

Antibody Structure

59.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Postoperative changes in cervical hemodynamics and cognitive function following cervical lymphatic-venous surgery in Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers.

Journal of medicinal chemistry·2026
Same author

Boosting peptide half-life: enabling efficient generation of Fc-peptide conjugates.

Chemical science·2026
Same author

Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments.

The Journal of experimental medicine·2026
Same author

Glutathione-Responsive Fragmentation of Heteronorbornadiene-Based Thiovinyl Sulfones in Glioma Cells.

Bioconjugate chemistry·2026
Same author

Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis.

ACS chemical biology·2026

相关实验视频

Updated: Jun 10, 2025

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
09:06

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

20.8K

特定站点的四重功能化抗体

Toby Journeaux1, Michael B Geeson1, Thomas V Murray2

  • 1Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.

Angewandte Chemie (International ed. in English)
|October 18, 2024
PubMed
概括

新的多有效载荷抗体-药物联合体 (ADC) 通过将多个功能附加到单个抗体上来克服瘤抵抗. 这一突破使得高度均的ADC具有多达四个不同的有效载荷,用于增强癌症治疗.

关键词:
抗体是一种抗体.抗体与药物的结合物.生物结合的生物结合多功能抗体药物合物 多功能抗体药物合物特定站点的蛋白质修饰

更多相关视频

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.8K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K

相关实验视频

Last Updated: Jun 10, 2025

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
09:06

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

20.8K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.8K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K

科学领域:

  • 生物结合化学 生物结合化学
  • 瘤学 治疗学 治疗学
  • 蛋白质工程是指蛋白质工程.

背景情况:

  • 抗体-药物联合体 (ADC) 显示临床成功,但由于瘤异质性和耐药性而面临限制.
  • 由于这些挑战,现有的ADC往往在有效性方面扎.
  • 多重有效载荷ADC,在单个抗体上具有多个不同的有效载荷,正在作为解决方案出现.

研究的目的:

  • 开发具有高度均的多功能抗体结合物,具有多个不同的有效载荷.
  • 克服当前ADCs在治疗异质和耐药瘤方面的局限性.
  • 为下一代ADC开发建立一个新的平台.

主要方法:

  • 利用了多个正交点特定位点的蛋白质修饰策略.
  • 在独特的抗体部位上具有多达四种不同功能的工程抗体结合.
  • 使用特定站点的循环烯 (CPO) 基试剂用于有效载荷的附着.

主要成果:

  • 成功生成了高度同质的多功能抗体合物.
  • 证明了在单个抗体上安装多达四个不同的功能的能力.
  • 实现了第一个同质的多有效载荷ADC,有效载荷数量超过2.

结论:

  • 这项工作提出了一种创新的方法,用于创建先进的多有效载荷ADC.
  • 开发的方法有助于创建具有增强治疗潜力的下一代ADC.
  • 这些结合物的同质性和高有效载荷能力提供了对抗瘤耐药性的有希望的策略.